Christopher R. Cline, CHIEF FINANCIAL OFFICER at Travere Therapeutics, Inc. (TVTX), sold 20,000 shares at $35.01 ($700K) on 2025-12-01, disclosed to the SEC on 2025-12-03.
Scheduled sale ($700k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2026-05-06 | $115K | — | Filing → |
| TVTX | SELL | 2026-04-15 | $349K | — | Filing → |
| TVTX | SELL | 2026-02-05 | $56K | — | Filing → |